Ariad, Specialised Therapeutics Australia sales and marketing update

Ariad granted Specialised Therapeutics exclusive, Australian commercialization rights for Iclusig ponatinib in patients with Philadelphia-positive (Ph+) leukemias. Specialised Therapeutics will be responsible for obtaining marketing authorization and pricing and reimbursement approval of Iclusig and will assist Ariad in any subsequent regulatory submissions for the product in Australia. The deal term is seven years from the first Iclusig sale after reimbursement approval.

Ariad submitted an Australian marketing application in 3Q13 for Iclusig to treat chronic myelogenous leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). The company said Australian approval and launch are slated for 4Q14. Prior to launch, Ariad and Specialised Therapeutics will make Iclusig available to patients under a special access program. ...